Ascletis Unveils Groundbreaking Fixed-Dose Combination Therapy for Obesity Management Ascletis Pharma announces a new fixed-dose combination of ASC30 and ASC39 aimed at obesity treatment, highlighting promising pharmacokinetics and patient compliance.

Ascletis Unveils Groundbreaking Fixed-Dose Combination Therapy for Obesity Management #USA #Hong_Kong #ASC30 #Ascletis_Pharma #ASC39

ASC39: A Promising Oral Small Molecule for Obesity Management in Clinical Trials Ascletis Pharma's ASC39 shows remarkable efficacy and selectivity in obesity treatment. The drug is poised for FDA review and clinical trials.

ASC39: A Promising Oral Small Molecule for Obesity Management in Clinical Trials #USA #Hong_Kong #Obesity_Treatment #Ascletis_Pharma #ASC39